Tokyo - Delayed Quote JPY

Stella Pharma Corporation (4888.T)

292.00 +2.00 (+0.69%)
At close: April 26 at 3:15 PM GMT+9
Key Events
Loading Chart for 4888.T
DELL
  • Previous Close 290.00
  • Open 290.00
  • Bid 292.00 x --
  • Ask 294.00 x --
  • Day's Range 286.00 - 295.00
  • 52 Week Range 229.00 - 366.00
  • Volume 43,700
  • Avg. Volume 169,296
  • Market Cap (intraday) 9.118B
  • Beta (5Y Monthly) 1.06
  • PE Ratio (TTM) --
  • EPS (TTM) -25.32
  • Earnings Date May 10, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.

www.stella-pharma.co.jp

46

Full Time Employees

March 31

Fiscal Year Ends

Related News

Performance Overview: 4888.T

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

4888.T
2.46%
Nikkei 225
13.36%

1-Year Return

4888.T
18.89%
Nikkei 225
33.50%

3-Year Return

4888.T
54.09%
Nikkei 225
30.24%

5-Year Return

4888.T
--
Nikkei 225
29.97%

Compare To: 4888.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4888.T

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    9.12B

  • Enterprise Value

    7.53B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    35.88

  • Price/Book (mrq)

    3.41

  • Enterprise Value/Revenue

    29.64

  • Enterprise Value/EBITDA

    -9.90

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -12.06%

  • Return on Equity (ttm)

    -28.94%

  • Revenue (ttm)

    254M

  • Net Income Avi to Common (ttm)

    -764M

  • Diluted EPS (ttm)

    -25.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.56B

  • Total Debt/Equity (mrq)

    36.44%

  • Levered Free Cash Flow (ttm)

    --

Company Insights: 4888.T

People Also Watch